Wednesday
May012019

SPARCtool updated to version 9

version 9 release notes

www.sparctool.com

SPARCtool

  • NEW annual risk of bleeding on NO THERAPY udpated to be patient-specific using sex and age from the “baseline cohort” (most applicable) in Selak et al. JAMA. 2018;319(24):2507–2520
  • NEW Net Clinical Benefit estimates. Estimates strokes/systemic embolisms prevented per major bleed caused. These are time-independent (i.e. they apply to any unit of time). Values <1 mean more major bleeds are caused than SSE prevented. Values >1 mean more SSE are prevented than bleeds caused.
  • NEW stroke and bleeding risks are now based on the linear predictor function of the respective prediction model derivation/validation study rather than on the actual risks in each stratum in those studies. This improves the reliability of the risk estimates by eliminating sporadic values (e.g. bleed risk less with HAS-BLED score 5 than score 4) and allows risk predictions for scores above those seen in actual studies (e.g. HAS-BLED >5) by extrapolating.
  • [coming soon]“Other Attributes” of each antithrombotic therapy to support shared decision-making conversations

SPARCmobile

  • [coming soon] update to v.9 as above
  • [coming soon] “Other Attributes” of each antithrombotic therapy to support shared decision-making conversations